Context Therapeutics (CNTX) Depreciation & Amortization (CF) (2022 - 2026)

Context Therapeutics has disclosed Depreciation & Amortization (CF) across 5 years of filings, most recently posting $4687.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $4687.0, up 15.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $16883.0 (up 36.51% YoY), and the FY2025 annual result was $16251.0, up 49.35% from the prior year.
• Depreciation & Amortization (CF) came in at $4687.0 for Q1 2026 at Context Therapeutics, up from $4065.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $4687.0 in Q1 2026 to a low of $2568.0 in Q4 2023.
• The 5-year median for Depreciation & Amortization (CF) is $3193.0 (2022), against an average of $3320.7.
• Across the five-year window, Depreciation & Amortization (CF) decreased 19.6% in 2023 and surged 58.29% in 2025, its largest moves.
• Context Therapeutics' Depreciation & Amortization (CF) stood at $3194.0 in 2022, then decreased by 19.6% to $2568.0 in 2023, then grew by 14.25% to $2934.0 in 2024, then jumped by 38.55% to $4065.0 in 2025, then grew by 15.3% to $4687.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $4687.0 (Q1 2026), $4065.0 (Q4 2025), and $4066.0 (Q3 2025), per Business Quant data.